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Abstract
Background: Multifollicular ovarian stimulation (MOS) is widely used in IVF and the compliance to treatment is
deeply influenced by the tolerability of the medication(s) used and by the ease of self-administration. This
prospective, controlled, randomised, parallel group open label, multicenter, phase III, equivalence study has been
aimed to compare the clinical effectiveness (in terms of oocytes obtained) and tolerability of subcutaneous (s.c.)
self-administered versus classical intramuscular (i.m.) injections of Merional, a new highly-purified hMG
preparation.
Methods: A total of 168 normogonadotropic women undergoing IVF were enrolled. Among them, 160 achieved
pituitary suppression with a GnRH-agonist long protocol and were randomised to MOS treatment with Merional
s.c. or i.m. They started MOS with a standard hMG dose between 150–300 IU, depending upon patient's age, and
underwent a standard IVF procedure.
Results: No statistically significant difference in the mean number of collected oocytes (primary endpoint) was
observed between the two study subgroups (7.46, SD 4.24 vs. 7.86, SD 4.28 in the s.c. and i.m. subgroups,
respectively). As concerns the secondary outcomes, both the pregnancy and the clinical pregnancy rates were
comparable between subgroups. The incidence of adverse events was similar in the two groups (2.4% vs. 3.7%,
respectively). Pain at injection site was reported only the i.m. group (13.9% of patients).
Conclusion: Merional may be used by s.c. injections in IVF with an effectiveness in terms of retrieved oocytes
that is equivalent to the one obtained with i.m administration and with a better local tolerability. With the
limitations due to the sample size af this study, s.c. and i.m. administration routes seem to have the same overall
safety.
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Background
Multifollicular ovarian stimulation (MOS) with gonado-
trophins is an integral part of various assisted reproduc-
tive technologies (ART), including standard in-vitro
fertilization (IVF) and intracytoplasmic sperm injection
(ICSI). The hormonal control of multiple follicular
growth is crucial in determining the quality and yield of
oocytes and consequently the availability of embryos to
transfer in utero, and has a relevant effect on the treatment
outcome [1].
Human Menopausal Gonadotrophin (hMG) has been in
use for over 30 years in women with WHO group I or II
ovulatory disorders. This medication currently represents
a widespread, safe and effective treatment choice for MOS
in ART [2]. Nevertheless, hMG preparations are extracted
from the urine of post-menopausal women, and small
peptidic contaminants are usually detectable in the com-
mercially available preparations [3,4]. As a consequence
of these technical limits, the s.c. employment of extractive
hMG, although well acceptable by patients wishing to
self-administer the drug, is limited, and i.m. administra-
tion is suggested [5].
Recently recombinant gonadotrophins, which are virtu-
ally free from aspecific contaminants, have been made
available and have been introduced on the market [6,7].
These drugs can be self-administrated by s.c. injection [8]
and although on the average more expensive than hMG
[9], they appear to be associated with a better compliance.
Given that the current literature is still insufficient to
definitively establish which gonadotrophin preparation
(urinary or recombinant) is more effective in IVF and the
available data are contradictory [10-13], attention has
been recently turned on costs, safety and tolerability of
available formulations.
Merional® (hMG) is a newly purified hMG preparation
containing 75 IU of follicle stimulating hormone (FSH)
activity and 75 IU of LH activity. It is produced using a
patented purification method and is registered and com-
mercially available in 15 countries worldwide. Merional®
is characterized by an high degree of purification leading
to the following final specific activity of the individual
hormone components: LH > 1,000 IU/mg, FSH > 3,000
IU/mg, hCG > 6,000 IU/mg. This purity level may theori-
cally allow s.c. self-administration, but its clinical effec-
tiveness when administered s.c. to IVF patients has not yet
been clarified.
This prospective, controlled, randomised, parallel group
open label, multicenter, phase III, equivalence study has
been aimed to compare the clinical effectiveness, tolera-
bility (both local and systemic) and safety of Merional®
s.c. administration versus i.m. injection in normogonado-
trophic patients undergoing MOS in an IVF program.
Methods
Overall study design and patients' selection
This equivalence study was carried out according to a pro-
spective, controlled, randomised, parallel group open
label, multicentre design. The ethics committe of each
Department participating in the study gave its written
approval to the study design. A total number of 168 nor-
mogonadotropic women were scheduled to be included
in the study in 4 investigational Centres, that used homo-
geneous procedures to accomplish IVF cycles throughout
the whole time period of investigation. The number of
patients recruited by each Centre was 42, 38, 51, and 37,
respectively. Following written informed consent, patients
with normal ovulatory cycles, aged 20–40 years, with a
Body Mass Index (BMI) between 20 and 28 kg/m2, were
enrolled and submitted to IVF/ICSI therapy with hus-
band's semen. The following exclusion criteria were
adopted: a) basal FSH levels ≥ 9 IU/L and/or documented
ovarian failure; b) ascertained or presumptive hypersensi-
tivity to Merional® components; c) presence of an ovarian
cyst(s) or of ovarian enlargement not due to polycystic
ovarian syndrome; d) patients undergoing oocyte dona-
tion; e) presence of an abnormal uterine bleeding of
unknown origin; f) documented poor ovarian responsive-
ness (requirement of at least 300 IU/d of FSH or hMG) in
previous IVF cycles; g) hormonal treatments (e.g. corticos-
teroids or oral contraceptives) in the 30 days preceding
the beginning of the study; h) presence of a documented
thyroid or adrenal dysfunction or of other endocrinologi-
cal diseases; i) presence of systemic diseases (e.g. malig-
nant tumors, severe renal and/or hepatic dysfunctions,
diabetes mellitus, thrombophlebitis, cardiac diseases, epi-
lepsy, etc.); l) presence of any contraindication toward
pregnancy; m) presence of any anatomical abnormality of
the reproductive apparatus (e.g. uterine myoma, etc.).
Determination of sample size
The number of retrieved oocytes at oocyte pick-up (OPU)
was retained as the primary end-point and equivalence
parameter, and an equal mean number of retrieved
oocytes in the two treatment arms was the null hypothe-
sis.
According to this equivalence experimental design and
choosing α = 0.05 and β = 0.20, a minimum number of
80 patients per treatment arm was calculated to be appro-
priate.
Removal of patients from the study protocol
Patients could be removed from the study for any of the
following reasons: a) no ovarian response to medication
or excessive risk of ovarian hyperstimulation syndromeReproductive Biology and Endocrinology 2007, 5:45 http://www.rbej.com/content/5/1/45
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(OHSS); b) appearance of adverse events or of a concom-
itant illness; c) violation of the protocol (e.g. contempora-
neous use of other medications not compatible with the
inclusion criteria); d) patient's will to quit the protocol; e)
uncompleted (or complete loss of) follow up.
The investigators had to specify the cause of patient's
removal in the 'Study Drop-Out Form' in the 'Case Record
Form'.
Ovarian stimulation
Patients were randomised using a computer-assisted 1:1
randomization to undergo MOS with either Merional®
administered subcutaneously (s.c.) or by intramuscular
(i.m.) injections. Since treatment subgroups were defined
according to administration route, no blinding procedure
could be adopted toward both patients and doctors mon-
itoring MOS. Anyway, embryologists were "blind" as they
did not know to which treatment arm were the patients
assigned.
All patients received a standard GnRH-agonist long proto-
col using Triptorelin (Decapeptyl® 0.1, IPSEN, Italy) at the
daily dose of 0.1 mg s.c. starting on the 21st day of the
cycle preceding IVF treatment. The achievement of pitui-
tary desensitisation was confirmed by transvaginal ultra-
sound (no evidence of ovarian activity, endometrial
thickness < 5 mm) and circulating estradiol assessment
(< 50 pg/ml). Patients showing pituitary down-regulation
started Merional® treatment, whereas patients with ovar-
ian cysts at ultrasound and/or endometrial thickness ≥
5 mm and/or E2 levels > 50 pg/mL went on with GnRH-
agonist for 5 further days and were checked again to assess
pituitary suppression; only in case they achieved it, the
ovarian stimulation with Merional® was began. Overall,
160 patients out of the 168 initially chosen could start
MOS. Merional® starting dose was scheduled according to
the patient's age: it was 150 IU/d in patients < 35 years,
225 IU between 35 and 38 years, 300 IU between 38 and
40 years. Although not as accurate as antral follicle count
(AFC) or basal FSH level, age was used to chose the start-
ing FSH dose because of its lack of subjectivity (vs. AFC)
and lack of difference among assay methods (vs. basal
FSH) that allowed the four recruiting Centers to be very
homogeneous. After the sixth stimulation day, the hMG
dose was eventually adjusted according to the ovarian
response assessed by serum E2 and US measurement of
follicular number and size; dose corrections were sched-
uled in advance as the daily dose could be increased or
decreased by a maximum of 150 IU of hMG. Transvaginal
US and E2 serum levels measurement were performed on
the first day of stimulation and after 7 days, as well as
every second day thereafter. Merional®  administration
continued until the criteria for triggering the final follicu-
lar maturation (one follicle ≥ 18 mm diameter plus at
least two other follicles ≥ 16 mm, with appropriate estra-
diol levels) were met; in case of a poor response, ovarian
stimulation was anyway stopped after 18 days. Ten thou-
sand IU of hCG (Gonasi, AMSA, Italy) were given i.m. 34–
36 hrs prior to transvaginal OPU. After recovering the
oocytes, fertilization was achieved by either standard IVF
or ICSI techniques and embryo transfer was performed
after 48–72 hrs of in vitro culture using a soft catheter.
Transvaginal progesterone (400 mg) was administered
daily for 14 days and a urinary pregnancy test was then
performed; in case of a positive test, the number of gesta-
tional sacs and the presence of embryonic heart beat were
assessed by transvaginal US after further 3 weeks.
Effectiveness and safety
In order to evaluate the treatment effectiveness, the
number of retrieved oocytes was chosen as the primary
endpoint, and the power calculation was made according
to it. In addition, the following secondary end-points
were considered: stimulation length (days), cumulative
hMG dose, E2 area under the curve (AUC0-t calculated
according to a trapezoidal rule and adjusted with respect
to baseline) and peak concentration (CMAX), fertilization
rate, pregnancy rate (positive urinary hCG)/cycle) and
clinical pregnancy rate (US-assessed foetal heartbeat)/
cycle.
The safety of Merional® was assessed using blood tests and
by giving to the patients a self-evaluation well-being ques-
tionnaire. The time of onset, severity and duration of any
adverse reaction was recorded, and any action and/or
pharmacological treatment adopted to face it was regis-
tered. The risk of OHSS was considered so high to justify
cycle cancellation when more that 20 follicles developed
above 12 mm diameter and/or serum estradiol exceeded
3500 pg/ml. As to tolerability, any red area surrounding
the most recent injection site was recorded, as well as the
eventual presence of pain, itching, or tenderness at the
injection site.
Hormonal assays
The enzyme-linked fluorescent assay (ELFA) technique
(Vidas Oestradiol II, BioMérieux, France) was used for
measuring serum E2  concentrations. This commercial
assay has the following characteristics: detection limit (the
lowest concentration detectable as different from zero
with a 95% probability) 0.03 pg/mL, intra- and inter-
assay variation coefficients <7%.
Statistical analysis
Statistical analyses to assess effectiveness and safety were
carried out on the population exposed to Merional®, thus
excluding those patients who were enrolled in the study
but did not achieve pituitary suppression and conse-
quently did not receive hMG.Reproductive Biology and Endocrinology 2007, 5:45 http://www.rbej.com/content/5/1/45
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The absence of significant differences in the baseline char-
acteristics between the two subgroups was assessed by the
Student t and the χ2 tests.
In order to assess differences between the two study sub-
groups, variables showing a normal distribution of the
data at Lilliefors test were tested by unpaired Student-t-
test, while in presence of a non-normal distribution, the
non parametric Mann-Whitney U-test was used. Differ-
ences having a binomial distribution (e.g. pregnancy rate,
foetal heart beat rate) were tested by χ2 test. The Schuir-
mann's test was used to test equivalence in the primary
outcome as well as in the secondary outcome variables.
The patients' subjective tolerance judgement and the pres-
ence of a high OHSS risk in the two subgroups were com-
pared according to Mantel-Haenszel χ2 test for trends. Any
difference between the two treatment subgroups were
declared to be significant in presence of a two-tailed p
value < 0.05.
Data management was performed using the Microsoft
SQL Server® version 2000. Statistical calculations were per-
formed with SAS® 8.2 installed on a Pentium 4. The statis-
tical package EquivTest was used for equivalence
calculations.
Results
A total number of 168 patients were enrolled in the study
on the basis of the inclusion criteria (Fig. 1); 85 of them
were randomly allocated in the s.c. administration group,
while 83 were assigned to the i.m. administration group.
The treatment subgroups were not significantly different
in terms of any of the baseline characteristics analyzed,
included the semen quality and the proportion of IVF and
ICSI procedures (Table 1).
Two and 3 patients in the mentioned subgroups, respec-
tively, did not achieve the pituitary down-regulation and
were consequently removed from the protocol. In the two
subgroups, 83 patients in the s.c. and 80 in the i.m. arm,
respectively, started treatment with Merional®. Among
them, 77 (92.8%) and 73 (91.2%), respectively, com-
pleted the MOS up to oocyte pick-up (OPU). The reasons
for dropping out during MOS are shown in Figure 1. The
starting dose of Merional® was adjusted (increased) in one
patient of the i.m. subgroup due to inadequate ovarian
response, and in three patients of the s.c. subgroup due to
patient's mistake in self-administration. Dose reduction
due to excessive ovarian response was necessary in 8
patients of the i.m. group and 13 patients of the s.c. group.
The reported death of one patient after starting stimula-
tion was not related to the treatment as it was due to a car
accident.
The analysis of the primary end-point (number of
retrieved oocytes) made by the Schuirmann test showed
therapeutic equivalence between s.c. and i.m. Merional® in
terms of oocytes retrieved at OPU. No statistically signifi-
cant difference was observed for most secondary end-
points including the pregnancy rate and the clinical preg-
nancy rate (Table 2). Only the total hMG dose was signif-
icantly lower in the s.c. than in the i.m. subgroup (2168.0
± 729.55 vs. 2595.1 ± 951.2 IU, respectively; p < 0.01),
and the stimulation length was shorter in the s.c. than in
the i.m. subgroup (13.8 ± 1.7 vs.14.6 ± 2.1 days, respec-
tively; p < 0.05) (Table 2).
The recorded incidence of adverse effects was overall very
low and similar in the two subgroups (2.4% vs. 3.7% of
patients in the s.c. and i.m. subgroups, respectively); these
adverse effects were headache, or aspecific abdominal
pain, both not clearly related to the drug's intake. Blood
chemistry tests during MOS showed no changes in com-
parison to baseline values in both subgroups (not
shown). Excessive OHSS risk was found in 2 out of 83
(2.4%) patients of the s.c. subgroup and in 2 out of 80
(2.5%) patients in the i.m. subgroup. Pain at injection site
was recorded in 13.9% of patients in the i.m. subgroup,
and in none in the s.c. subgroup.
Discussion
Although IVF may be performed retrieving an oocyte from
the single follicle developing during a spontaneous ovula-
tory cycle [14] or collecting immature oocytes in the
Table 1: Baseline characteristics of the patients included in the study.
Merional s.c. Merional i.m. P value
N. of patients randomised 85 83
Age (years)* 34.6 ± 4.9 34.4 ± 5.2 NS
Diagnosis of male factor (%) 48 51 NS
Diagnosis of unexplained infertility (%) 18 17 NS
Diagnosis of tubal factor (%) 24 25 NS
Endometriosis (%) 10 7 NS
Proportion of ICSI (%) 53 54 NS
* Values expressed as mean ± SD.Reproductive Biology and Endocrinology 2007, 5:45 http://www.rbej.com/content/5/1/45
Page 5 of 7
(page number not for citation purposes)
Schematic representation of the distribution of the 168 enrolled patients throughout the study Figure 1
Schematic representation of the distribution of the 168 enrolled patients throughout the study.
Patients randomised 
n = 168 
Down-regulation 
not achieved 
n = 3 
Merional  
s.c. 
n = 85
Merional 
i.m. 
n = 83
Embryo transfer 
n = 77 
Embryo transfer 
n = 73 
Cancelled  n = 7 
2 OHSS high risk 
2 Pick-up not perfomed 
1AEs (death) 
1= hMG administration >18 days
1= GnRH-a intake interrupted 
Cancelled  n = 6 
2 OHSS high risk 
2 inadequate response 
2 coasting
Started Merional 
i.m. 
n = 80
Started Merional 
s.c. 
n = 83
Down-regulation 
not achieved 
n = 2 
Table 2: Outcome of ovarian stimulation and IVF in patients who received Merional by s.c.vs. i.m. injections.
Merional s.c. Merional i.m. P value
N. of patients starting MOS 83 80
Duration of MOS (days)* 13.8 ± 1.7 14.6 ± 2.1 0.02
hMG total dose (IU)* 2168.6 ± 729.55 2595.1 ± 951.2 0.002
AUC0-t of E2 (log-transformed 
pmol/L*days)*
8.7 ± 0.6 8.8 ± 0.5 NS
CMAX of E2 (pmol/L) * 2215.5 ± 1288.4 2416.2 ± 1258.5 NS
Completed COS cycles (OPUs) 77 73
N. of oocytes retrieved/OPU* 8.0 ± 3.8 8.6 ± 3.7 NS
N. of fertilized oocytes/OPU* 3.6 ± 2.7 4.0 ± 3.0 NS
N. of embryo transfers (ETs) 77 73
hCG positive tests 32 25
Pregnancy rate/started cycle (%) a 38.5 31.2 NS
Pregnancy rate/ET (%)a 41.5 34.2 NS
Clinical pregnancies 21 19
Clinical pregnancy rate/started 
cycle (%) b
25.3 23.7 NS
Clinical pregnancy rate/ET (%)b 27.3 26.0 NS
* Values expressed as mean ± SD.
a Women who had positive-urine pregnancy test performed 14 days after embryo transfer.
b Women who had US evidence of foetal heartbeatReproductive Biology and Endocrinology 2007, 5:45 http://www.rbej.com/content/5/1/45
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middle follicular phase and maturing them in vitro
[15,16], multifollicular ovarian stimulation (MOS) with
gonadotropins is by far the most widely used method to
obtain fertilizable oocytes in IVF treatment cycles. The
possibility of fertilizing several eggs that have matured in
follicles growing during controlled ovarian stimulation is
still considered an important advantage in comparison to
the before mentioned alternatives, that are used almost
only in very selected subsets of patients, such as women
with the polycystic ovary syndrome [17].
Several protocols for gonadotropin administration in IVF
have been studied and proposed in the last twenty-five
years, and relevant efforts have been made to introduce on
the market new products coupling effectiveness, safety,
and subjective tolerability. A recent study about the com-
pliance of patients to MOS has demonstrated that the
route of administration of gonadotropins deeply affects
the patient's tolerance to the treatment, and that the sub-
cutaneous (s.c.) route is the one with the best impact on
the patient's quality of life, and tends to be preferred to
the intramuscular (i.m.) route [18]. Some bioequivalence
studies have also shown that both FSH [19] and hMG [20]
have the same biological and pharmacokinetic properties
when injected i.m. or s.c., and show the same effectiveness
in stimulating follicular recruitment and growth.
The present study was designed to assess the effectiveness
of the s.c. administration of Merional®, a new highly-puri-
fied form of hMG, in inducing MOS in IVF patients, and to
compare it with the same drug given i.m at comparable
doses. The possibility to obtain the same number of
oocytes available for fertilization using a highly purified
hMG given in an easy and very tolerable way is intriguing
also in view of prescribing the drug for self-administration.
The randomisation procedure achieved two subgroups
(s.c. vs. i.m. Merional®) that resulted to be well balanced
as far as all relevant patients' baseline characteristics are
concerned. On the whole, the study population was ade-
quate in terms of homogeneity and size to support an
informative comparison toward the primary end-points
of effectiveness (number of oocytes) and safety (incidence
of adverse effects). Although it was not possible to organ-
ize a fully "blind" study (patients obviously knew the way
of administration, and doctors following MOS also knew
because patients in the i.m. subgroup sometimes asked to
be helped for i.m. injections), both doctors performing
OPU (in most cases) and embryologists (always) were
"blind" as they did not know to which subgroup each
patient belonged. As a consequence, the number of
retrieved oocytes (primary end-point) as well as all IVF
procedures in the laboratory may be considered as "blind
study" findings, not affected by the patient's or the
doctor's will.
The main observation emerging from this prospective ran-
domised trial is the bioequivalence of s.c and i.m. Meri-
onal®  administration in terms of oocyte production
during MOS and recovery at OPU. In fact, patients sub-
mitted to MOS using s.c Merional® had a comparable
number of oocytes retrieved at OPU than women receiv-
ing the same preparation by the classical i.m. route. We
are aware that an equal number of retrieved oocytes does
not necessarily mean to have the same chance of obtain-
ing fertilized oocytes, transferable embryos, and finally a
pregnancy; oocyte quality, in fact, is the major determi-
nant of IVF outcome and its relative importance is by far
higher than oocyte number [21]. The present trial does
not show a full therapeutic equivalence between s.c. and
i.m. Merional® because it was powered according to the
primary end-point "number of retrieved oocytes" and it is
underpowered to show equivalence between the two
routes of Merional® administration in terms of IVF treat-
ment success. We cannot therefore state that s.c. and i.m.
hMG administration routes are equivalent in terms of
overall effectiveness on IVF cycle, but still we can say that
we got the same number of oocytes in the two subgroups
and we did not observe a trend toward better IVF results
in either of the two subgroups.
In the present study, patients treated with s.c. administra-
tion showed a significantly shorter stimulation and they
also received a significantly lower total Merional® dose.
Interestingly, a similar observation was reported by Voort-
man et al. [19], that compared i.m vs. s.c. recombinant
FSH and reported a better ovarian response with the s.c.
administration route despite an absolute bioequivalence
in pharmacokinetic. Similarly, pharmacokinetic studies
evaluating Merional® s.c. and i.m.administration routes in
healthy female volunteers showed comparable pharma-
cokinetic profiles (unpublished IBSA report on file), but
still Merional® intake was significantly lower using s.c.
administration (-16.4% on average), with a consequent
reduction in the economical cost per cycle.
As for safety, the incidence of adverse effects was very lim-
ited and not significantly different in the two study sub-
groups. Laboratory tests did not provide evidence of
treatment-related changes in either subgroup, and neither
the self-evaluation well-being assessment, nor the clinical
observation of the patients' well-being accomplished by
doctors monitoring MOS showed any difference accord-
ing to the drug administration route. The incidence of
OHSS was low in both subgroups and also the need to
cancel the stimulation cycle because of excessive OHSS
risk was very limited.
As for subjective tolerability, pain at injection site was sig-
nalled by 13.9% of patients in the i.m. subgroup, and byReproductive Biology and Endocrinology 2007, 5:45 http://www.rbej.com/content/5/1/45
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nobody in the s.c. subgroup, suggesting some advantage
of the s.c. route with respect to tolerability.
In conclusion, the results of the present study support the
use of Merional® by s.c. injection, that allows to obtain a
similar effectiveness in terms of oocyte yield, a compara-
ble incidence of adverse effects and cycle cancellation and
probably has a better subjective tolerability with respect to
the classical i.m. route.
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